Comparative Pharmacology
Head-to-head clinical analysis: PROSTAPHLIN versus STAPHCILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROSTAPHLIN versus STAPHCILLIN.
PROSTAPHLIN vs STAPHCILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prostaphlin (oxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1 and PBP3, leading to inhibition of transpeptidation and cell lysis. It is resistant to staphylococcal beta-lactamases.
Semisynthetic penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
250-500 mg IM or IV every 4-6 hours for moderate to severe infections. For oral use: 250-500 mg every 6 hours on empty stomach.
1-2 g IV every 4-6 hours.
None Documented
None Documented
0.4-0.8 hours in adults with normal renal function; prolonged in renal impairment (up to 4-6 hours in anuria).
0.5-1 hour in adults with normal renal function; prolonged to 2-4 hours in renal impairment. Infants: 1-2 hours.
Primarily renal (70-80% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Primarily renal (70-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary excretion (<5%) and fecal elimination (<1%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic